You are here
Home > Infectious Disease > Veillonella 

Background:

------------------------------------------------------------------------------
Anaerobic Gram-Negative cocci
------------------------------------------------------------------------------
Veillonella
1] Veillonella parvula
2] V. atypica, V. dispar, and V. montpellierensisVeillonella:

  • Gram-negative anaerobic cocci.
  • Well known for its lactate fermenting abilities.
  • Normal bacterium in the intestines and oral mucosa of mammals.
  • Have been rarely implicated in cases of osteomyelitis and endocarditis  (e.g. Veillonella parvula.)
  • Source: https://en.wikipedia.org/wiki/Veillonella

top of page

Therapy:

Important considerations:  The choice of an agent should be based on local antimicrobial sensitivities, site of infection, cost, and comorbid conditions.   Generally, the most common agents/regimens are listed first.

Very little is known about the virulence factors or treatment strategies for this rare pathogen.
Penicillin was considered to be the antimicrobial agent of choice, however, high levels of resistance have been reported in some cases.  Veillonella strains are usually isolated as part of a polymicrobial process.

Veillonella is resistant to the following antimicrobials:

  • Vancomycin
  • Tetracycline
  • Aminoglycosides
  • Ciprofloxacin

Possible treatment regimens -  Check MIC's before treating:

  1. Amoxicillin 500mg orally three times daily or Ampicillin 1-2 grams IV every 4-6 hours
  2. Augmentin 875/125 mg orally twice daily  OR  Ampicillin-sulbactam (Unasyn®) 1.5 - 3.0 grams IV q6h
  3. Metronidazole 500mg IV/PO every 6 hours
  4. Cefoxitin 1-2 gm IV q6h
  5. Clindamycin  Usual: 600-900mg IV every 6 or 8 hours or 150 to 450mg orally every 6-8 hours
  6. Chloramphenicol 50-100 mg/kg/day IV in divided doses every 6 hours (Maximum daily dose is 4 grams e.g. 1 gram q6h)

Reference(s)

Disclaimer

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer